



November 22, 2017

Adamas to Present at Two Upcoming Investor Conferences

EMERYVILLE, Calif., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences:

- | Richard A. King, the company's Chief Operating Officer, is scheduled to present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at 10:30 a.m. ET
- | Gregory T. Went, Ph.D., the company's Founder, Chairman and Chief Executive Officer, is scheduled to present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on Thursday, November 30, 2017 at 8:20 a.m. ET

In addition, the company is scheduled to host meetings at the Global Mizuho Investor Conference on Tuesday, December 5, 2017.

The presentations will be webcast live from the investor relations section of the Adamas website at <http://ir.adamaspharma.com/events.cfm>. Archived versions of the webcasts will be available via replay for 30 days following the presentations.

About Adamas Pharmaceuticals, Inc.

At Adamas, we believe in the power and promise of medicines derived from a deep understanding of time-dependent biology. Our expertise lies in uncovering and mapping the relationship between disease and drug activity. From there, we strive to create medicines with therapeutic profiles that match the pattern of disease to drive a more significant and durable clinical effect. This understanding of time-dependent biological processes informs our every innovation, targeting advancement in treatment of chronic neurologic disorders. Our portfolio includes: GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; ADS-5102 in development for the treatment of multiple sclerosis walking impairment and additional indications in Parkinson's disease; and ADS-4101, a high-dose, modified-release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information, please visit www.adamaspharma.com.

Contact:

Ashleigh Barreto

Director, Corporate Communications & Investor Relations

Adamas Pharmaceuticals, Inc.

510-450-3567

ir@adamaspharma.com

 Primary Logo

Source: Adamas Pharmaceuticals, Inc.

News Provided by Acquire Media